Minerva Neurosciences, Inc. (NERV) Stock
Key stats
- Market cap
- $127.58M
- Price / Earnings ratio
- -0.4x
- EPS (TTM)
- -$33.94
- Volume
- Loading
- 52-week high
- $8.80
- 52-week low
- $1.96
Source: third-party data provider, as of November 13, 2026
Compare with NERV
Recent news

All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
NERV

Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NERV

TOPS, SURG: The Top 5 Short Squeeze Stocks This Week
TOPS, SURG: The Top 5 Short Squeeze Stocks This Week
NERV
Technical indicators
- RSI 14
- 47.46
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.24
- MACD histogram
- 0.08
- SMA 50
- $3.10
- Price below SMA 50
- EMA 50
- $3.02
- Price below EMA 50
- SMA 200
- $4.83
- Price below SMA 200
- EMA 200
- $4.25
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
NERV

Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NERV

TOPS, SURG: The Top 5 Short Squeeze Stocks This Week
TOPS, SURG: The Top 5 Short Squeeze Stocks This Week
NERV
About Minerva Neurosciences, Inc.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Remy Luthringer Ph.D. | Executive Chairman, CEO & Member of Scientific Advisory Board | 1961 |
| Mr. Frederick W. Ahlholm CPA | Senior VP, CFO & Secretary | 1966 |
| Mr. Joseph Reilly | Senior VP & COO | 1975 |
| Mr. Anthony Aliquo | Chief Accounting Officer & Principal Accounting Officer | 1987 |
| Mr. William B. Boni | Vice President of Investor Relations & Corporate Communications | 1952 |
| Mr. James O'Connor | Chief Business Officer & General Counsel | 1974 |
| Prof. Michael Davidson M.D. | Member of Scientific Advisory Board & Chief Medical Officer | 1950 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 47.46
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.24
- MACD histogram
- 0.08
- SMA 50
- $3.10
- Price below SMA 50
- EMA 50
- $3.02
- Price below EMA 50
- SMA 200
- $4.83
- Price below SMA 200
- EMA 200
- $4.25
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $10.00
- Average
- $10.00
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -24.7 | -11.5 | ||||||||||
| 2022 | -10.3 | -11.7 | +20.1 | -41.4 | -20.0 | -1.5 | -25.3 | +337.2 | -4.6 | -72.9 | +28.3 | -55.7 |
| 2023 | +58.3 | -7.3 | -24.2 | +68.7 | +58.8 | +42.1 | +4.3 | -19.4 | -17.7 | -28.0 | +58.3 | -15.2 |
| 2024 | +37.4 | -69.1 | -1.9 | -6.7 | +6.2 | +10.4 | +5.9 | |||||
| 2026 | -7.9 | +15.5 | -19.1 | +14.7 | -22.7 | +14.9 | -25.2 | -28.2 | +8.9 |




